Helius Medical Technologies Takes Steps for Market Access
Helius Medical Technologies, Inc. (Nasdaq:HSDT) is on a mission to ensure equitable access to its groundbreaking Portable Neuromodulation Stimulator (PoNS) device. This innovative neurotech company is dedicated to offering new therapeutic solutions for individuals battling balance and gait deficits, particularly those affected by multiple sclerosis (MS). In an update that highlights their commitment, Helius announced key efforts and strategies aimed at achieving fair market access.
Confronting Pricing Challenges
Recently, the company expressed its concern over the proposed pricing structure for the PoNS Mouthpiece. According to Dane Andreeff, the President and CEO of Helius, the current evaluation by the Centers for Medicare & Medicaid Services (CMS) inaccurately aligns the pricing of the PoNS Controller with codes intended for different technologies. Such mapping fails to acknowledge the unique functionality of the PoNS device, which operates differently than traditional TENS units, focusing on enhancing neural plasticity rather than merely suppressing pain.
Impacts on Patients and Market Access
The repercussions of these pricing decisions have been significant, as they currently obstruct Medicare patients from receiving prescriptions for the PoNS device. The company advocates for a comprehensive reassessment of their case, armed with substantial evidence presented during the recent HCPCS Level 2 Public meeting. Helius hopes that CMS will reconsider its stance, understanding the true potential and effectiveness of the PoNS system.
Business Update Call Scheduled
Adding to the conversation, Helius is set to host a business update call to provide stakeholders with the latest information concerning their ongoing market access efforts for the PoNS device. This call is scheduled to happen soon, allowing the company to outline its future strategies and reiterate its dedication to delivering essential therapies to those affected by neurological disorders.
Reimbursement Process and Delays
The company has faced delays in the reimbursement process, as CMS has recently issued pricing determinations that Helius believes are based on incomplete data. This extended process not only affects patient access to PoNS Therapy but has also impacted the company’s market value and its ability to raise capital for ongoing operations. Helius remains steadfast in its commitment to improve access for patients, clearly indicating potential adjustments in their strategy based on the outcomes of these discussions.
About the PoNS Device and Its Therapy
The Portable Neuromodulation Stimulator (PoNS) represents a leading-edge solution aimed at treating gait deficits stemming from multiple sclerosis and other neurological conditions. This non-invasive device is designed to be utilized in conjunction with therapeutic exercises, providing patients the chance to enhance their mobility and regain a sense of independence.
Clinical Efficacy and Applications
Clinical evidence supports the effectiveness of the PoNS device in improving both balance and gait performance, contributing to a lowered risk of falls in patients who utilize it. Its therapeutic potential has garnered attention in several countries, with regulatory approvals highlighting its importance in the field of neurorehabilitation.
Future Considerations for Helius Medical Technologies
As Helius Medical Technologies continues to navigate the complexities of market access and reimbursement, the company emphasizes its long-term vision of utilizing technology to aid those with severe neurological conditions. Through continued advocacy and transparent communication with stakeholders, Helius aims to advocate for innovations that truly matter to patients’ lives.
Frequently Asked Questions
1. What is the PoNS device?
The PoNS device is a portable neuromodulation therapy tool designed to improve balance and gait by delivering neurostimulation through the mouth.
2. How does Helius Medical Technologies intend to overcome pricing challenges?
Helius is actively engaging with CMS, providing evidence to challenge current pricing decisions and advocating for fair market access for patients.
3. What impact do current pricing determinations have on patients?
The proposed pricing obstructs Medicare patients from receiving the necessary prescriptions for the PoNS device, limiting their access to essential therapy.
4. Why is the PoNS considered an important treatment option?
This device has demonstrated efficacy in enhancing mobility and reducing fall risks in patients with neurological conditions, especially MS.
5. How can interested parties stay updated on Helius Medical Technologies?
Interested individuals can follow Helius Medical Technologies through their official communications, including business update calls and press releases, for the latest information about their efforts and developments.
